Arcellx, Inc.
ACLX
Rank in Stocks
#2785
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Share Price
$115.07
Last synced: 2026-05-15
Market Cap
$6.73B
Change (1 day)
0.00%
Change (1 year)
32.28%
Country
US
Trade Arcellx, Inc. (ACLX)
Category
Healthcare
EPS for Arcellx, Inc. (ACLX)
EPS as of December 2025 TTM: $-4.07
According to Arcellx, Inc. latest financial reports and stock price the company's current EPS (TTM) is $-4.07. At the end of 2023 the company had a EPS of $-1.47 a decrease compared to its 2022 EPS that were of $-4.28.
EPS history for Arcellx, Inc. from 2018 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-4.07 | 103.50% |
| 2024 | $-2.00 | 36.05% |
| 2023 | $-1.47 | -65.65% |
| 2022 | $-4.28 | 120.62% |
| 2021 | $-1.94 | 31.97% |
| 2020 | $-1.47 | 182.69% |
| 2019 | $-0.52 | -98.96% |
| 2018 | $-50.17 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $17.32 | -525.55% |
US
|
|
| $-7.98 | 96.07% |
US
|
|
| $-5.29 | 29.98% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -781.57% |
NL
|
